LONDON - Astex Technology Ltd. agreed to a multi-target drug discovery deal with Boehringer Ingelheim International GmbH, in which each target could yield up to $45 million in research and development costs and milestones for Astex, up to the point of commercialization. (BioWorld International)

LONDON - Ark Therapeutics Group plc successfully completed its initial public offering last week, raising £55 million (US$102 million) as it joined the main market of the London Stock Exchange, the first biotechnology company to do so in more than three years. (BioWorld International)